Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
- Associated Therapies
- -
Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma
- Conditions
- Interventions
- First Posted Date
- 2013-03-05
- Last Posted Date
- 2015-06-17
- Lead Sponsor
- Italian Sarcoma Group
- Target Recruit Count
- 38
- Registration Number
- NCT01804374
- Locations
- 🇮🇹
Fondazione del Piemonte per l'Oncologia IRCC Candiolo, Candiolo, Torino, Italy
A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC)
- Conditions
- Interventions
- First Posted Date
- 2013-02-28
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- Indiana University
- Registration Number
- NCT01801163
- Locations
- 🇺🇸
Indiana University, Indianapolis, Indiana, United States
Sorafenib + mFOLFOX for Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2013-01-25
- Last Posted Date
- 2020-04-22
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT01775501
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2013-01-07
- Last Posted Date
- 2018-11-20
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 26
- Registration Number
- NCT01762150
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Xijing Hospital, Xi'an, Shanxi, China
🇨🇳Sun Yat-sen university cancer center, Guangzhou, Guangdong, China
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2013-01-04
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 954
- Registration Number
- NCT01761266
- Locations
- 🇬🇧
Facility # 3, London, Greater London, United Kingdom
🇬🇧Facility # 2, London, Greater London, United Kingdom
🇰🇷Facility # 6, Seoul, Korea, Republic of
A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
- Conditions
- Interventions
- First Posted Date
- 2012-12-21
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 5
- Registration Number
- NCT01754987
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2013-05-17
- Lead Sponsor
- Eanm Research Ltd
- Registration Number
- NCT01736878
- Locations
- 🇩🇪
University Hospital Ulm, Clinic for Nuclear Medicine, Ulm, Baden-Wuerttemberg, Germany
Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-11-21
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 193
- Registration Number
- NCT01730937
- Locations
- 🇺🇸
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)
- Conditions
- Interventions
- First Posted Date
- 2012-11-12
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT01724606
- Locations
- 🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
The Effect of Sorafenib on Portal Pressure
- Conditions
- Interventions
- First Posted Date
- 2012-10-26
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Yale University
- Target Recruit Count
- 10
- Registration Number
- NCT01714609
- Locations
- 🇺🇸
Brigham & Womens, Boston, Massachusetts, United States
🇺🇸VA Medical Center West Haven, West Haven, Connecticut, United States
🇺🇸New York University Langone Medical Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.